Abstract
Cytokeratins are polypeptides that constitute a subclass of intermediate filaments in epithelial cells. The aim of the present study was to evaluate the clinical usefulness of the serum evaluation of M3/M21 in patients with ovarian cancer. This retrospective study comprises 75 patients suffering from ovarian cancer FIGO stages Ia-III. M3/M21 reached a sensitivity of 78%, a specificity of 85%, a PPV of 89% and a NPV of 83% using a cut-off level of 45 U 1(-1). Forty-four women developed recurrent disease after complete remission during the observation period. M3/M21 showed lead time effects in 19 patients, ranging from 2 to 8 months (median 3.2 months). Elevated M3/M21 serum levels before therapy were associated with a poor overall survival (log-rank test, P = 0.02). Considering these preliminary results, the value of M3/M21 as a serum tumour marker, i.e. to evaluate the tumour burden, seems promising.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Børmer O. P. From tissue polypeptide antigen to specific cytokeratin assays. Tumour Biol. 1994;15(4):185–187. [PubMed] [Google Scholar]
- Devine P. L. All cytokeratin assays are not the same. Eur J Clin Chem Clin Biochem. 1994 Dec;32(12):939–940. [PubMed] [Google Scholar]
- Gion M., Mione R., Becciolini A., Balzi M., Correale M., Piffanelli A., Giovannini G., Saccani Jotti G., Fontanesi M. Relationship between cytosol TPS, TPA and cell proliferation. Int J Biol Markers. 1994 Apr-Jun;9(2):109–114. doi: 10.1177/172460089400900208. [DOI] [PubMed] [Google Scholar]
- Moll R., Franke W. W., Schiller D. L., Geiger B., Krepler R. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell. 1982 Nov;31(1):11–24. doi: 10.1016/0092-8674(82)90400-7. [DOI] [PubMed] [Google Scholar]
- Sabbatani S., Monti M., Fini A. Tissue polypeptide antigen (TPA) modifications in hepatic cirrhosis, aggressive chronic hepatitis, persistent chronic hepatitis, and in minimal pathology. Int J Biol Markers. 1988 Apr-Jun;3(2):127–128. doi: 10.1177/172460088800300209. [DOI] [PubMed] [Google Scholar]
- Schwartz P. E., Cracchiolo B. M., Cole L. A. Clinical applications of urinary gonadotropin peptides (UGP) in gynecologic oncology. Anticancer Res. 1996 Jul-Aug;16(4B):2135–2139. [PubMed] [Google Scholar]
- Sundström B. E., Stigbrand T. I. Cytokeratins and tissue polypeptide antigen. Int J Biol Markers. 1994 Apr-Jun;9(2):102–108. doi: 10.1177/172460089400900207. [DOI] [PubMed] [Google Scholar]
- Thigpen J. T., Vance R. B., Khansur T. Second-line chemotherapy for recurrent carcinoma of the ovary. Cancer. 1993 Feb 15;71(4 Suppl):1559–1564. doi: 10.1002/cncr.2820710422. [DOI] [PubMed] [Google Scholar]